News | Nuclear Imaging | September 20, 2016

PET Probe Images Breast Cancer’s Ability to Foil Treatment

Researchers believe the technique could be used to guide further treatment to avoid pathway blocks

PET probes, breast cancer, surface receptor changes, MGH study, Memorial Sloan Kettering

After molecularly targeted therapy with an AKT inhibitor, the receptor tyrosine kinase (RTK) HER3 increases in this particular tumor, but the RTK EGFR does not. In this example, starting HER3 inhibitor therapy in addition to AKT inhibitor therapy is likely to be beneficial, but the addition of EGFR inhibitor therapy is not likely to be beneficial for treating this tumor. Image courtesy of Massachusetts General Hospital, Boston.

September 20, 2016 — Cancer biologists know that inhibitor-mediated feedback loop changes (increased expression of a cell surface receptor in response to target inhibition) can result in breast cancer treatment failure and the need for additional therapy. A recent study by researchers at Massachusetts General Hospital in Boston and at Memorial Sloan Kettering in New York City shows that imaging of these cell surface receptor changes with positron emission tomography (PET) probes specific to epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 3 (HER3) directly addresses this unmet need in cancer therapy decision-making, while avoiding the need for repeated biopsies. The study is reported in the September issue of The Journal of Nuclear Medicine.

“In some cases, cancer cells can adapt quickly to overcome these pathway blocks by increasing the upstream signaling receptors that help drive these pathways — analogous to cancer cells turning a faucet a few turns to increase the water pressure through a hose to overcome a kink we placed in the hose downstream,” explains Umar Mahmood, M.D., Ph.D., of the Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital in Boston.

“We can image that upregulation of cell surface signaling receptors and, in fact, can image which specific surface receptors have increased expression after downstream targeted inhibitor therapy is started,” he adds. “This allows the rational addition of a second therapy to block this inhibitor-mediated signaling receptor increase. In a game of chess with the cancer cell, we have made a move by blocking a signaling node. The cancer cell has responded by increasing a cell surface receptor to overcome this block, and our imaging allows us to make an optimal move to specifically block the type of cell surface receptor the cell increased.”

The imaging studies, using newly developed PET probes specific to EGFR and HER3, show that changes in receptor tyrosine kinases (RTK) expression indicative of resistance to phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) inhibitors can be seen within days of therapy initiation, and are of sufficient magnitude to be useful for clinical interpretation as this technology is translated. Noninvasive PET monitoring of these RTK feedback loops should help to rapidly assess resistance to PI3K and AKT inhibitors and guide selection of an appropriate, additional therapeutic regimen for the individual patient.

Authors of the article “Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance” include Eric Wehrenberg-Klee, N. Selcan Turker, Pedram Heidari, Benjamin Larimer, Dejan Juric, and Umar Mahmood, Massachusetts General Hospital, Boston, Massachusetts; José Baselga and Maurizio Scaltriti, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

This research was supported by NIH U01CA084301, P50CA127003, and U01CA143056; by a “Stand Up to Cancer” Dream Team Translational Research Grant, a Program of the Entertainment Industry Foundation (SU2C-AACRDT0209) and the Breast Cancer Research Foundation; and by the Dubai Harvard Foundation for Medical Research (DHFMR, grant number 223439).

For more information: www.jnm.snmjournals.org

Related Content

Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Opto-Acoustic Imaging Helps Differentiate Breast Cancer Molecular Subtypes
News | Ultrasound Women's Health | December 20, 2018
Seno Medical Instruments Inc. (Seno Medical) reported results of a study demonstrating that morphologic and functional...
Densitas Enters Platform Partnership With Blackford
News | Breast Density | December 19, 2018
Breast imaging analytics company Densitas Inc. announced the signing of a new Alliance Partner Agreement with Blackford...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RSNA Study Shows Real-Time Indicator Improves Mammographic Compression
News | Mammography | December 12, 2018
Sigmascreening recently announced that more than 100,000 women have had mammography exams with the Sensitive Sigma...